Radiolabeled RGD-DTPA-Tyr3-octreotate for receptor-targeted radionuclide therapy

Area of Science:

• Oncology
• Radiopharmaceutical Chemistry
• Molecular Imaging and Therapy

Background:

• Many cancers overexpress cell surface somatostatin receptors (sst2).
• Targeted delivery of therapeutic agents to these receptors can enhance treatment efficacy.
• Current somatostatin-based therapies can be improved by incorporating apoptosis-inducing moieties.

Purpose of the Study:

• To develop and investigate a novel radiopeptide for cancer treatment.
• To create a hybrid molecule targeting sst2 receptors and inducing apoptosis.
• To evaluate the synthesis, in vitro, and in vivo characteristics of this new radiopharmaceutical.

Main Methods:

• Synthesis of a hybrid peptide comprising Tyr3-octreotate, DTPA, and an RGD peptide.
• In vitro studies to assess receptor specificity and internalization in sst2-positive tumor cells.
• In vivo studies in rats to evaluate tumor uptake and biodistribution of the radiolabeled hybrid peptide.

Main Results:

• The radiolabeled hybrid peptide demonstrated rapid and sst2-specific internalization into tumor cells.
• In vitro internalization was effectively blocked by unlabeled octreotide.
• In vivo tumor uptake in rats was comparable to established radiolabeled somatostatin analogs.

Conclusions:

• The developed radiopeptide effectively targets sst2-expressing tumors.
• The hybrid molecule facilitates receptor-mediated internalization and apoptosis induction.
• This novel radiopeptide holds potential for significantly enhancing the therapeutic efficacy of somatostatin-based cancer treatments.